SCHEMBL161684

SCHEMBL161684

CC(C)OC(=O)c1cccc(O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.67
CA1 P00915 7/20 0.67
CA2 P00918 7/20 0.67
CA9 Q16790 7/20 0.67
CA7 P43166 6/20 0.67
CA14 Q9ULX7 6/20 0.67
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HTT P42858 2/20 0.58
MAPT P10636 1/20 0.58
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
CA6 P23280 1/20 0.52
KDM4E B2RXH2 1/20 0.52
EGLN2 Q96KS0 1/20 0.52
PDCD1 Q15116 1/20 0.51
CD274 Q9NZQ7 1/20 0.51
ALDH1A1 P00352 2/20 0.50
PARP1 P09874 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43683 0.88 NPC1 (0.65) CA12CA1CA2CA9CA7
SCHEMBL28199513 0.86 CA12 (0.49) CA12CA1CA2CA9CA7
SCHEMBL28163777 0.83 CA12 (0.46) CA12CA1CA2CA9CA7
SCHEMBL27683331 0.81 RAB9A (0.62) CA12CA1CA2CA9CA7
SCHEMBL30678268 0.81 NPC1 (0.62) CA12CA1CA2CA9CA7
SCHEMBL6233392 0.81 NPC1 (0.62) CA12CA1CA2CA9CA7
SCHEMBL161683 0.81 NPC1 (0.58) CA12CA1CA2CA9CA7
SCHEMBL6057062 0.81 RAB9A (0.58) CA12CA1CA2CA9CA7
SCHEMBL23484189 0.80 ADRB2 (0.56) CA12CA1CA2CA9CA7
SCHEMBL23066461 0.80 CA12 (0.92) CA12CA1CA2CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3946240-B1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL HENKEL AG & CO KGAA (DE) 2025-10-15 EP claimed
US-20220211602-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2022-07-07 US claimed
EP-3946240-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL Henkel AG & Co. KGaA (DE) 2022-02-09 EP claimed
WO-2020200545-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2020-10-08 WO claimed
CN-119823439-A Method for efficiently recycling waste plastics 东莞市众一新材料科技有限公司 2025-04-15 CN disclosed
US-20220211602-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2022-07-07 US disclosed
EP-3946240-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL Henkel AG & Co. KGaA (DE) 2022-02-09 EP disclosed
WO-2020200545-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2020-10-08 WO disclosed
WO-2020200545-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL HENKEL AG & CO. KGAA (DE) 2020-10-08 WO disclosed
CN-106462059-B Resist material, resist composition, and resist pattern forming method 三菱瓦斯化学株式会社 2020-07-28 CN disclosed
CN-104761752-B Graphene inorganic agent, graphene enhancing complex material and preparation method thereof 广东劲胜智能集团股份有限公司 2018-03-13 CN disclosed
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed
US-4051122-A Disazo pigments containing tetracarboxylic acid ester groups CIBA-GEIGY CORPORATION (US) 1977-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 CA12 4471/4885CA1 2770/4885CA2 2000/4885
US-20220211602-A1 INCREASING THE STABILITY OF AGENTS FOR TREATING KERATIN MATERIAL KRT18, CCNA1, CCNA2 CA12 699/4885CA1 710/4885CA2 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.